Observations placeholder
Viramune
Identifier
005608
Type of Spiritual Experience
Background
A description of the experience
Viramune
also marketed under the name Nevirapine . It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection and AIDS. As with other antiretroviral drugs, HIV rapidly develops resistance if nevirapine is used alone, so recommended therapy consists of combinations of three or more antiretrovirals. Nevirapine is not effective against HIV-2, as the pocket of the HIV-2 reverse transcriptase has a different structure, which confers intrinsic resistance to the NNRTI class. Resistance to nevirapine develops rapidly if viral replication is not completely suppressed.
Most common Viramune side effects
- Fever - (964 reports)
- Maternal drugs affecting foetus - (828 reports)
- Drug exposure during pregnancy - (682 reports)
- Hypertriglyceridaemia - (439 reports)
- Premature baby - (425 reports)
- Agranulocytosis - (401 reports)
- Rashes - (387 reports)
- Blood lactic acid increased - (374 reports)
- Complications of maternal exposure to therapeutic drugs - (361 reports)
- Nausea - (353 reports)
Severe or life-threatening skin reactions have been observed in 1.5% of patients. Nevirapine may cause severe or life-threatening liver toxicity, usually emerging in the first six weeks of treatment.
On Jan, 31, 2017 9,182 people reported to have side effects when taking Viramune. Among them, 12 people (0.13%) have Hallucination
On Jan, 31, 2017 9,182 people reported to have side effects when taking Viramune. Among them, 13 people (0.14%) have Hallucination, Auditory